

UK NEQAS for H&I - SCHEME 3 - HLA ANTIBODY SPECIFICITY ANALYSIS

CLASS II HLA ANTIBODY SPECIFICITY ANALYSIS OF 306/2018

DESPATCHED ON 13 NOVEMBER 2018

DPB1* Antibodies - NOT ASSESSED						
Consensus % reported	04:01			28:01		
	Absent 2.8%			Not Assessed 12.5%		
Lab no.	spec	tech	MFI	spec	tech	MFI
9						
11						
12						
14						
15						
19						
20						
23						
24						
25						
26						
28						
34						
35						
38						
39						
41						
42						
45						
48						
51						
54						
58						
62						
100	04:01	L	< 2000	28:01	L	2000-5000
112				28:01	L	2000-5000
114						
116						
117						
119						
120						
133				28:01	L	2000-5000
136						
142						
143						
145						
149				28:01	L	2000-5000
157						
160						
162						
165						
169						
181						
185						
194						
195						
197						
206						
212						
214				28:01	L	5001-9999
216						
218				28:01	L	2000-5000
222						
227						
229	NT					
230				28:01	L	5001-9999
232						
242						
252						
267	04:01	L	< 2000	28:01	L	< 2000
268						
273						
277						
284						
292						
293						
294						
302						
303						
309						
351						
361				28:01	L	2000-5000
392	NT					
401	NT					
411						

Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O =

Number reporting	2 < 2000		9 < 2000	
Sepcificity	2	< 2000	9	< 2000
Total number of participants	72	2	72	1
		2000-5000		2000-5000
		0		6
		5001-9999		5001-9999
		0		2
		> 10000		> 10000
		0		0

UK NEQAS for H&I - SCHEME 3 - HLA ANTIBODY SPECIFICITY ANALYSIS

CLASS II HLA ANTIBODY SPECIFICITY ANALYSIS OF 306/2018

DESPATCHED ON 13 NOVEMBER 2018

DQA1* Antibodies - NOT ASSESSED									
Consensus % reported	03:01 Absent 2.8%			03:02 Not Assessed 22.2%			03:03 Absent 4.2%		
	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI
9									
11									
12				03:02	L	< 2000			
14				03:02	L	2000-5000	03:03	L	< 2000
15									
19									
20									
23									
24				03:02	L	< 2000			
25				03:02	L	< 2000			
26				03:02	L	< 2000			
28				03:02	L	< 2000			
34				03:02	L	< 2000			
35									
38									
39									
41				03:02	L	2000-5000			
42									
45	03:01	L	< 2000	03:02	L	< 2000	03:03	L	< 2000
48									
51									
54									
58									
62									
100									
112									
114									
116									
117				03:02	L	< 2000			
119									
120									
133									
136									
142				03:02	L	< 2000			
143									
145									
149									
157									
160									
162									
165									
169									
181				03:02	L	< 2000			
185									
194									
195	03:01	L	< 2000	03:02	L	< 2000	03:03	L	< 2000
197									
206									
212									
214									
216									
218									
222									
227				03:02	L	< 2000			
229	NT								
230									
232									
242									
252									
267									
268									
273									
277				03:02	L	< 2000			
284									
292									
293									
294									
302									
303				03:02	L	< 2000			
309									
351									
361									
392	NT								
401	NT								
411									

Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other

Number reporting	03:01			03:02			03:03		
Specificity	2	< 2000		16	< 2000		3	< 2000	
Total number of participants	72	2		72	14		72	3	
		2000-5000			2000-5000			2000-5000	
		0			2			0	
		5001-9999			5001-9999			5001-9999	
		0			0			0	
		> 10000			> 10000			> 10000	
		0			0			0	

UK NEQAS for H&I - SCHEME 3 - HLA ANTIBODY SPECIFICITY ANALYSIS

CLASS II HLA ANTIBODY SPECIFICITY ANALYSIS OF 306/2018

DESPATCHED ON 13 NOVEMBER 2018

DPA1* Antibodies - NOT ASSESSED

Consensus No specificities detected

% reported

Lab no.

9	No specificities detected
11	No specificities detected
12	No specificities detected
14	No specificities detected
15	No specificities detected
19	No specificities detected
20	No specificities detected
23	No specificities detected
24	No specificities detected
25	No specificities detected
26	No specificities detected
28	No specificities detected
34	No specificities detected
35	No specificities detected
38	No specificities detected
39	No specificities detected
41	No specificities detected
42	No specificities detected
45	No specificities detected
48	No specificities detected
51	No specificities detected
54	No specificities detected
58	No specificities detected
62	No specificities detected
100	No specificities detected
112	No specificities detected
114	No specificities detected
116	No specificities detected
117	No specificities detected
119	No specificities detected
120	No specificities detected
133	No specificities detected
136	No specificities detected
142	No specificities detected
143	No specificities detected
145	No specificities detected
149	No specificities detected
157	No specificities detected
160	No specificities detected
162	No specificities detected
165	No specificities detected
169	No specificities detected
181	No specificities detected
185	No specificities detected
194	No specificities detected
195	No specificities detected
197	No specificities detected
206	No specificities detected
212	No specificities detected
214	No specificities detected
216	No specificities detected
218	No specificities detected
222	No specificities detected
227	No specificities detected
229 NT	No specificities detected
230	No specificities detected
232	No specificities detected
242	No specificities detected
252	No specificities detected
267	No specificities detected
268	No specificities detected
273	No specificities detected
277	No specificities detected
284	No specificities detected
292	No specificities detected
293	No specificities detected
294	No specificities detected
302	No specificities detected
303	No specificities detected
309	No specificities detected
351	No specificities detected
361	No specificities detected
392 NT	No specificities detected
401 NT	No specificities detected
411	No specificities detected

Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = O

Number reporting	
Specificity	0 < 2000
Total number of participants	72
	0
	2000-5000
	0
	5001-9999
	0
	> 10000
	0

UK NEQAS for H&I - SCHEME 3 - HLA ANTIBODY SPECIFICITY ANALYSIS

CLASS II HLA ANTIBODY SPECIFICITY ANALYSIS OF 307/2018

DESPATCHED ON 13 NOVEMBER 2018

DQA1* Antibodies - NOT ASSESSED

Lab no.	01:02			02:01			03:01			04:01			05:01			05:03			05:05			06:01		
	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI
9																								
11																								
12																								
14																								
15																								
19																								
20																								
23																								
24																								
25																								
26																								
28																								
34																								
35																								
38																								
39																								
41																								
42																								
45																								
48																								
51																								
54																								
58																								
62																								
100																								
112																								
114																								
116																								
117																								
119																								
120																								
133																								
136																								
142	01:02 L	< 2000	02:01 L	2000-5000	03:01 L	2000-5000	04:01 L	2000-5000	05:01 L	5001-9999	05:01 L	5001-9999	05:03 L	05:03 L	05:05 L	05:05 L	< 2000	< 2000	06:01 L	< 2000				
143																								
145																								
149																								
157																								
160																								
162																								
165																								
169																								
181																								
185																								
194																								
195																								
197																								
206																								
212																								
214																								
216																								
218																								
222																								
227																								
229 NT																								
230																								
232																								
242																								
252																								
267																								
268																								
273																								
277																								
284																								
292																								
293																								
294																								
302																								
303																								
309																								
351																								
361																								
392 NT																								
401 NT																								
411																								

Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other

Number reporting	01:02			02:01			03:01			04:01			05:01			05:03			05:05			06:01		
Specificity	1	< 2000		5	< 2000		5	< 2000		6	< 2000		18	< 2000		9	< 2000		10	< 2000		2	< 2000	
Total number of participants	72	1		72	1		72	2		72	3		72	0		72	1		72	10		72	1	
		2000-5000			2000-5000			2000-5000			2000-5000			2000-5000			2000-5000			2000-5000			2000-5000	
		0			3			3			3			10			1			0			0	
		5001-9999			5001-9999			5001-9999			5001-9999			5001-9999			5001-9999			5001-9999			5001-9999	
		0			0			0			0			7			0			0			0	
		> 10000			> 10000			> 10000			> 10000			> 10000			> 10000			> 10000			> 10000	
		0			0			0			0			1			0			0			0	

UK NEQAS for H&I - SCHEME 3 - HLA ANTIBODY SPECIFICITY ANALYSIS

CLASS II HLA ANTIBODY SPECIFICITY ANALYSIS OF 307/2018

DESPATCHED ON 13 NOVEMBER 2018

DPA1* Antibodies - NOT ASSESSED

Consensus % reported	No specificities detected
-------------------------	---------------------------

Lab no.	No specificities detected
9	No specificities detected
11	No specificities detected
12	No specificities detected
14	No specificities detected
15	No specificities detected
19	No specificities detected
20	No specificities detected
23	No specificities detected
24	No specificities detected
25	No specificities detected
26	No specificities detected
28	No specificities detected
34	No specificities detected
35	No specificities detected
38	No specificities detected
39	No specificities detected
41	No specificities detected
42	No specificities detected
45	No specificities detected
48	No specificities detected
51	No specificities detected
54	No specificities detected
58	No specificities detected
62	No specificities detected
100	No specificities detected
112	No specificities detected
114	No specificities detected
116	No specificities detected
117	No specificities detected
119	No specificities detected
120	No specificities detected
133	No specificities detected
136	No specificities detected
142	No specificities detected
143	No specificities detected
145	No specificities detected
149	No specificities detected
157	No specificities detected
160	No specificities detected
162	No specificities detected
165	No specificities detected
169	No specificities detected
181	No specificities detected
185	No specificities detected
194	No specificities detected
195	No specificities detected
197	No specificities detected
206	No specificities detected
212	No specificities detected
214	No specificities detected
216	No specificities detected
218	No specificities detected
222	No specificities detected
227	No specificities detected
229 NT	No specificities detected
230	No specificities detected
232	No specificities detected
242	No specificities detected
252	No specificities detected
267	No specificities detected
268	No specificities detected
273	No specificities detected
277	No specificities detected
284	No specificities detected
292	No specificities detected
293	No specificities detected
294	No specificities detected
302	No specificities detected
303	No specificities detected
309	No specificities detected
351	No specificities detected
361	No specificities detected
392 NT	No specificities detected
401 NT	No specificities detected
411	No specificities detected

Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O =

Number reporting Specificity	0	< 2000
Total number of participants	72	0
		2000-5000
		0
		5001-9999
		0
		> 10000
		0

UK NEQAS for H&I - SCHEME 3 - HLA ANTIBODY SPECIFICITY ANALYSIS

CLASS II HLA ANTIBODY SPECIFICITY ANALYSIS OF 308/2018

DESPATCHED ON 13 NOVEMBER 2018

Techniques used	Sample Treatment	High Background	Neq control serum batch	Allele Specific Antibodies	Luminex kit (lot)		Cut-off value		Control bead MFI		Control bead MFI		Luminex kit (lot)		Cut-off value		Control bead MFI		Control bead MFI		Luminex kit (lot)		Cut-off value		Control bead MFI		Control bead MFI		
					IgG	IgG	Positive	Negative	IgG	IgG	Positive	Negative	IgG	IgG	Positive	Negative	IgG	IgG	Positive	Negative	IgG	IgG	Positive	Negative	IgG	IgG	Positive	Negative	IgG
9 L	EDTA	No	19	DRB1*04:02	LS2A01	500	10171	74																					
11 L	EDTA	No	19	DRB1*04:02	LS2A01	1000	4791	32	LSM12	2.5	6665	81																	
12 L	EDTA	No	19	DRB1*04:02	LS2A01	500	9170	103																					
14 L	Heat inactivation, EDTA	No	19	DRB1*04:02	LS2A01	1500	10569	22.92																					
15 L	EDTA	No	19	DRB1*01:01, 04:02	LS2A01	1000	11945	68																					
19 L	EDTA	No		DRB1*04:02	LS2A01	1000	9165	72																					
20 C, L	EDTA	No		DRB1*04:02	LS2A01	1000	9464.18	40.46																					
23 L				DRB1*01:01																									
24 L	Adsorption beads, EDTA	Yes	19	DRB1*01:01, 04:02	LS2A01	1000	11984	53	LSM12	4.5	15332	202	LS2PRA	1000	15769	97	LSAII	1500/4.5			14428								
25 L	EDTA	No	19	DCB1*03:01, DQA1*05:05 & DQA1*05:03 only	LS2A01	1000	10168	65	LSAII	1500	15257	160																	
26 L	No treatment	No	19	DCB1*02:01, DQA1*05:01 only	LS2A01	500	12004	14																					
28 L	No treatment	No	19	DRB1*04:02	LS2A01	500	9684	75																					
34 L	EDTA	No	19	DRB1*04:02	LS2A01	1337	11245	21																					
35 L	EDTA	No	19	DRB1*04:02	LS2A01	1000	8329	58																					
38 L	EDTA	No	19	DRB1*01:01	LS2A01	1000	9462	84	LSAII	1000	19064	372																	
39 L	EDTA	No	19	DRB1*04:02	LS2A01	500	9591	11089																					
41 L	EDTA	No	19	DRB1*01:01, 04:02	LS2A01	2000	6880	28																					
42 L	EDTA	No	19	DRB1*04:02	LS2A01	500	7977	80																					
45 L	Adsorption beads, EDTA	No		DRB1*01:01	LS2A01	1500	12000	30																					
48 L	Heat inactivation	No	19	DRB1*04:02																									
51 L	EDTA	No		DRB1*01:01	LS2A01	1500	6727	40																					
54 L	EDTA	No	19	DRB1*04:02	LS2A01	1000	10157	53																					
58 L	EDTA	No	18	DRB1*01:01	LS2A01	1000	10415	101	LSM12	3.0	15337	165																	
62 L	EDTA	No	19	DRB1*04:02	LS2A01	1500	10666	62	LSAII	MFLPRA	17491	564																	
100 L	No treatment	No		DRB1*01:01	LSAII	750	12089	234																					
112 L	No treatment	No		DRB1*04:02	LSAII	500	19957	276																					
114 L	EDTA	No		DRB1*04:02	LS2A01	1000	8827	50																					
116 L	EDTA	No	19	DRB1*04:02	LS2A01	1000	8238	34	LSM12		9025	124																	
117 L	No treatment	No	19	DRB1*01:01	LS2A01	500	9067	30																					
119 L	EDTA	No	18	DRB1*04:02	LS2A01	1000	9028	24	LSM12	1.5	7809	21																	
120 L	EDTA	No		DRB1*01:01	LS2A01	500	8820	23																					
133 L	Heat inactivation	No	3005428	DRB1*01:01, 03:03, 03:02, 04:02, 08:01, 08:02, 11:01, 11:03, 11:04, 12:01, 12:02, 13:01, 13:03, 13:05, 14:01, 14:03, 14:04, 15:01, 15:02, 15:03, 16:01, 16:02	LSAII		16798	342																					
136 L	No treatment	No		DRB1*01:01	LS2A01	1000	10640	42																					
142 L	EDTA	No		DRB1*04:02	LS2A01	1000	9541	29																					
143 L	No treatment	No		DRB1*04:02	LS2A01	1000	13810	166																					
145 L	No treatment	No	16	DRB1*04:02	LS2A01	1000	6887	31																					
149 L	No treatment	No	19	DRB1*01:01, 04:02	LSAII	1000	21381	286																					
157 L	EDTA	No	19	DRB1*01:01, 04:02	LS2A01	1000	8629	2041																					
160 L	Adsorption beads	No	17	DRB1*01:01	LS2A01	1000	5777	31																					
162 L	EDTA	No		The One Lambda single antigen kit does not discriminate between DRB1*04:01 and 04:02, it reports DP4	LS2A01	1000	8557	28.4	LSM12	3	9802	23.8																	
165 L	No treatment	No	17	DRB1*01:01	LS2A01	48	7110	94																					
169 L	No treatment	No		DRB1*04:02	LS2A01	1000	5322	22																					
181 L	EDTA	No	19	DRB1*04:02	LS2A01	500	7337	34																					
185 L	EDTA	No		DRB1*04:02	LSAII	4	16324	193	LM2	2	19778	798	LMX	1	18209	101													
194 L	EDTA	No	18	DRB1*04:02	LS2A01	1000	10003	33																					
195 L	No treatment	No		DRB1*01:01	LS2A01	1000	10416	98																					
197 L	No treatment	No		DRB1*04:02																									
206 L	EDTA	No	271350	DRB1*04:02	LS2A01	1000	9644	74																					
212 L	No treatment	No		DRB1*01:01	LM2	2000	18343	250																					
214 L				DCB1*04:01, 04:02, 05:01, 05:02, 05:03, 06:01, 06:02, 06:03, 06:04	LSAII	750	15976	373																					
216 L	No treatment	No		DRB1*03:01, 03:02, 03:03, 08:01, 08:02, 11:01, 11:03, 11:04, 12:01, 12:02, 13:01, 13:03, 13:05, 14:01, 14:03, 14:04, 15:01, 15:02, 15:03, 16:01, 16:02																									
218 L	Adsorption beads	Yes	300389	DRB1*01:01, 02:02, 03:01	LM2	2500	15411	891																					
				DCB1*04:01, 04:02, 05:01, 05:02, 05:03, 06:04	LSAII	750	16543	277																					
				DRB1*01:01, 03:01, 03:02, 03:03, 04:02, 08:01, 08:02, 11:01, 11:03, 11:04, 12:01, 12:02, 13:01, 13:03, 13:05, 14:01, 14:03, 14:04, 15:01, 15:02, 15:03, 16:01, 16:02																									
				DRB1*01:01, 02:02, 03:01																									
222 L	No treatment	No		DRB1*04:02	LM2	800	18136	1114																					

UK NEQAS for H&I - SCHEME 3 - HLA ANTIBODY SPECIFICITY ANALYSIS

CLASS II HLA ANTIBODY SPECIFICITY ANALYSIS OF 309/2018

DESPATCHED ON 13 NOVEMBER 2018

DPB1* Antibodies - NOT ASSESSED																								
Consensus % reported	01:01			04:01			09:01			10:01			14:01			17:01			19:01			23:01		
	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI
9																								
11																								
12																								
14																								
15																								
19																								
20																								
23																								
24																								
25																								
26																								
28																								
34																								
35																								
38																								
39																								
41																								
42																								
45																								
48																								
51																								
54																								
58																								
62																								
100																								
112																								
114																								
116																								
117																								
119																								
120																								
133																								
136																								
142																								
143																								
145																								
149																								
157																								
160																								
162																								
165																								
169																								
181																								
185																								
194																								
195																								
197																								
206																								
212																								
214																								
216																								
218																								
222																								
227																								
229	NT																							
230																								
232																								
242																								
252																								
267																								
268																								
273																								
277																								
284																								
292																								
293																								
294																								
302																								
303																								
309																								
351																								
361																								
392	NT																							
401	NT																							
411	01:01 L	< 2000	04:01 L	< 2000			10:01 L	< 2000	14:01 L	< 2000			19:01 L	< 2000	23:01 L	< 2000								

Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other

Number reporting	01:01			04:01			10:01			14:01			17:01			19:01			23:01					
Sepcificity	1	< 2000		1	< 2000		1	< 2000		9	< 2000		14	< 2000		1	< 2000		1	< 2000		2	< 2000	
Total number of participants	72	1		72	1		72	1		72	6		72	10		72	1		72	1		72	2	
		2000-5000			2000-5000			2000-5000			2000-5000			2000-5000			2000-5000			2000-5000			2000-5000	
		0			0			0			2			4			0			0			0	
		5001-9999			5001-9999			5001-9999			5001-9999			5001-9999			5001-9999			5001-9999			5001-9999	
		0			0			0			1			0			0			0			0	
		> 10000			> 10000			> 10000			> 10000			> 10000			> 10000			> 10000			> 10000	
		0			0			0			0			0			0			0			0	

UK NEQAS for H&I - SCHEME 3 - HLA ANTIBODY SPECIFICITY ANALYSIS

CLASS II HLA ANTIBODY SPECIFICITY ANALYSIS OF 309/2018

DESPATCHED ON 13 NOVEMBER 2018

DQA1* Antibodies - NOT ASSESSED

Consensus	01:02
	Absent
% reported	1.4%

Lab no.	spec	tech	MFI
9			
11			
12			
14			
15			
19			
20			
23			
24			
25			
26			
28			
34			
35			
38			
39			
41			
42			
45			
48			
51			
54			
58			
62			
100			
112			
114			
116			
117			
119			
120			
133			
136			
142			
143			
145			
149			
157			
160			
162			
165			
169			
181			
185			
194			
195			
197			
206			
212			
214	01:02 L		< 2000
216			
218			
222			
227			
229	NT		
230			
232			
242			
252			
267			
268			
273			
277			
284			
292			
293			
294			
302			
303			
309			
351			
361			
392	NT		
401	NT		
411			

Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other

Number reporting	1	< 2000
Specificity		
Total number of participants	72	1
		2000-5000
		0
		5001-9999
		0
		> 10000
		0

UK NEQAS for H&I - SCHEME 3 - HLA ANTIBODY SPECIFICITY ANALYSIS

CLASS II HLA ANTIBODY SPECIFICITY ANALYSIS OF 309/2018

DESPATCHED ON 13 NOVEMBER 2018

DPA1* Antibodies - NOT ASSESSED									
Consensus % reported	01:03			02:01			02:02		
	Absent			Absent			Absent		
	1.4%			2.8%			1.4%		
Lab no.	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI
9									
11									
12									
14									
15									
19									
20									
23									
24									
25									
26									
28									
34									
35									
38									
39									
41									
42									
45									
48									
51									
54									
58									
62									
100									
112									
114									
116									
117									
119									
120									
133									
136									
142				02:01 L		< 2000			
143									
145									
149									
157									
160									
162									
165									
169									
181									
185									
194									
195									
197									
206									
212									
214									
216									
218									
222									
227									
229 NT									
230									
232									
242									
252									
267									
268									
273									
277									
284									
292									
293									
294									
302									
303									
309									
351									
361									
392 NT									
401 NT									
411	01:03 L		< 2000	02:01 L		< 2000	02:02 L		< 2000

Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other

Number reporting Specificity	1	< 2000	2	< 2000	1	< 2000
Total number of participants	72	1	72	2	72	1
		2000-5000		2000-5000		2000-5000
		0		0		0
		5001-9999		5001-9999		5001-9999
		0		0		0
		> 10000		> 10000		> 10000
		0		0		0

UK NEQAS for H&I - SCHEME 3 - HLA ANTIBODY SPECIFICITY ANALYSIS

CLASS II HLA ANTIBODY SPECIFICITY ANALYSIS OF 309/2018

DESPATCHED ON 13 NOVEMBER 2018

Techniques used	Sample Treatment	High Background	Neg control serum batch	Allele Specific Antibodies	Luminex kit (lot)	Cut-off value	Control bead MFI Positive	Control bead MFI Negative	Luminex kit (lot)	Cut-off value	Control bead MFI Positive	Control bead MFI Negative	Luminex kit (lot)	Cut-off value	Control bead MFI Positive	Control bead MFI Negative
IgG	IgG			IgG	IgG	IgG			IgG	IgG			IgG	IgG		
9 L	EDTA	No			LS2A01	1000	9000	80								
11 L	EDTA	No	19		LS2A01	1000	4756	17	LSM12	2.5	6214	42				
12 L	EDTA	No	19	DRB1*04:04 DRB03:01	LS2A01	500	10321	89								
14 L	Heat inactivation, EDTA	No	19	Would interpret as non-specific	LS2A01	1500	12047	31.09								
15 L	EDTA	No	19		LS2A01	1000	10111	45								
19 L	EDTA	No	19		LS2A01	1000	9631	25								
20 C, L	EDTA	No	19		LS2A01	1000	9030.46	16.38								
23 L	EDTA	No	19		LS2A01	1000	6737	22.77								
24 L	No treatment	No	19		LSM12	4.5	16468	120	LS2PRA	1000	14859	23				
25 L	No treatment	No	19													
26 L	No treatment	No	19		LS2A01		9796	57								
28 L	No treatment	No	19		LS2A01	500	8019	34								
34 L	EDTA	No	19		LS2A01	1386	10857	34								
35 L	EDTA	No	19		LS2A01	1000	9711	53								
38 L	EDTA	No	19		LS2A01	1000	11506	27	LSAII	1000	18721	155				
39 L	EDTA	No	19		LS2A01	1500	10187	39								
41 L	EDTA	No	19		LS2A01	2000	6911	22								
42 L	EDTA	No	19	DRB*03:01	LS2A01	500	10778	69								
45 L	Adsorption beads, EDTA	No			LS2A01	1500	16000	70								
48 L	Heat inactivation	No	19													
51 L	EDTA	No	19		LS2A01	1000	7046	59								
54 L	EDTA	No	19		LS2A01	1000	12815	182								
58 L	EDTA	No	18		LS2A01	1000	10060	60	LSM12	3.0	10984	65				
62 L	EDTA	No	19		LS2A01	1500	11000	41	LSAII	MFI/LRA	16538	237				
100 L				DQA1*01:02/DOB1*05:02	LSAII	750	12531	136								
112 L	No treatment	No			LSAII	500	19731	235								
114 L	EDTA	No			LS2A01	1000	9215	40								
116 L	EDTA	No	19		LSM12		9212	123								
117 L	No treatment	No	19		LS2A01	500	10649	20								
119 L	EDTA	No		DRB1*13:01	LS2A01	1000	6277		LSM12	1.5	6996	21				
120 L	EDTA	No			LS2A01	500	8736	18								
133 L	Heat inactivation	No	3005428	DRB3*03:01 DOB1*05:02	LSAII		16132	179								
136 L	No treatment	No			LS2A01	1000	10732	32								
142 L	EDTA	No			LS2A01	1000	9243	29								
143 L	No treatment	No			LS2A01	1000	14046	64								
145 L	No treatment	No	16		LS2A01	1000	6149	23								
149 L	No treatment	No			LSAII	1000	16645	232								
157 L	EDTA	No	19		LS2A01	1000	10408	24.62								
160 L	Adsorption beads	No	17		LS2A01	1000	6773	46								
162 L	EDTA	No			LS2A01	1000	9792	26.4	LSM12	3	10026	20.9				
165 L	No treatment	No	17		LS2A01		7683	46								
169 L	No treatment	No			LS2A01	1000	8162	24								
181 L	EDTA	No	19		LS2A01	500	8424	29								
185 L	EDTA	No			LSAII	4	17246	192	LM2	2	20455	95	LMX	1	17597	125
194 L	EDTA	No	18		LS2A01	1000	9831	30								
195 L	No treatment	No			LS2A01	1000	8427	44								
197 L	No treatment	No														
206 L	EDTA	Yes	271350	DRB3*03:01	LS2A01	1000	9840	71								
212 L	No treatment	No			LM2	1000	20150	300								
214 L				DRB1*11:01, 11:03, 11:04	LSAII	750	16120	204								
216 L	No treatment	No	3006369		LM2	1000	17713	105								
218 L	Adsorption beads	Yes		DOB1*05:02, DRB3*03:01	LSAII	750	17466	276								
222 L	No treatment	No			LM2	800	18246	105								
227 L																
229 L																
230 L	No treatment	No	3006531		LSAII	500	10000	500								
232 L	No treatment	No	19	All MFIs below 1200	LS2A01	1200	7599	25								
242 L	Adsorption beads	No			LSAII		17804	169								
252 L	No treatment	No			LM2		18324	165								
267 L	EDTA	No			LSAII		15237	135								
268 L	EDTA	No	19		LS2A01	2000	9395	31	LS2PRA	2000	7778	47				
273 L	No treatment	No			LS2A01	1500	10989	36								
277 L	EDTA	No	19		LS2A01	500	7206	27								
284 L					LS2A01	1000	9425	27	LSM12	5	10319	46				
292 L	EDTA	No			LS2A01	500	10041	30	LSM12	4.5	12682	52				
293 L	No treatment	No			LS2A01	500	8179	19								
294 L	No treatment	No		DOB1*05:02	LSAII		15025									
302 L	No treatment	No														
303 L	Heat inactivation, EDTA	No	19		LS2A01	1000	11712	44								
309 L	No treatment	No			LSAII	500	18000	150								
351 L	EDTA	No	19		LS2A01	1500	11599	34								
361 L	No treatment	No	3006531	DOB1*05:02	LSAII	500	16420	125								
392 L																
401 L																
411 L	No treatment	No	20	DRB1*07:01, 09:02, 13:01	LS2A01	X6	8152.4	50.92	LSM12	2.2	10538	61.64				

Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other

UK NEQAS for H&I - SCHEME 3 - HLA ANTIBODY SPECIFICITY ANALYSIS

CLASS III HLA ANTIBODY SPECIFICITY ANALYSIS OF 31/02/2018

DESPATCHED ON 13 NOVEMBER 2018

HLA specificity for assessment		DR8 Present 80.9%			DR9 Present 79.5%			DR10 Present 79.4%			DR51 Present 79.4%			DR52 Present 82.4%			DR53 Not Assessed 72.1%			DQ5 Present 86.8%			DQ6 Present 92.6%			DQ2 Not Assessed			DQ7 Present 75.0%			DQ8 Not Assessed 67.6%			DQ9 Not Assessed			DQ4 Not Assessed 73.5%		
Lab.no.	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI	spec	tech	MFI				
9																																								
11	DR8	L	>1000	DR9	L	5001-9999	DR10	L	>1000	DR51	L	5001-9999	DR52	L	>1000	DR53	L	5001-9999	DQ5	L	5001-9999	DQ6	L	5001-9999	DQ2	L	<2000	DQ7	L	2000-5000	DQ8	L	2000-5000	DQ9	L	2000-5000	DQ4	L	2000-5000	
12	DR8	L	5001-9999	DR9	L	5001-9999	DR10	L	5001-9999	DR51	L	5001-9999	DR52	L	5001-9999	DR53	L	5001-9999	DQ5	L	5001-9999	DQ6	L	5001-9999	DQ2	L	<2000	DQ7	L	2000-5000	DQ8	L	2000-5000	DQ9	L	2000-5000	DQ4	L	2000-5000	
14	DR8	L	>1000	DR9	L	5001-9999	DR10	L	>1000	DR51	L	5001-9999	DR52	L	2000-5000	DR53	L	5001-9999	DQ5	L	5001-9999	DQ6	L	5001-9999	DQ2	L	2000-5000	DQ7	L	2000-5000	DQ8	L	2000-5000	DQ9	L	2000-5000	DQ4	L	2000-5000	
15	DR8	L	5001-9999	DR9	L	2000-5000	DR10	L	2000-5000	DR51	L	2000-5000	DR52	L	2000-5000	DR53	L	2000-5000	DQ5	L	2000-5000	DQ6	L	2000-5000	DQ2	L	<2000	DQ7	L	<2000	DQ8	L	2000-5000	DQ9	L	<2000	DQ4	L	<2000	
19	NT																																							
20	DR8	L	>1000	DR9	L	5001-9999	DR10	L	>1000	DR51	L	5001-9999	DR52	L	>1000	DR53	L	2000-5000	DQ5	L	5001-9999	DQ6	L	>1000	DQ2	L	<2000	DQ7	L	2000-5000	DQ8	L	2000-5000	DQ9	L	2000-5000	DQ4	L	2000-5000	
23	DR8	L	5001-9999	DR9	L	5001-9999	DR10	L	5001-9999	DR51	L	5001-9999	DR52	L	5001-9999	DR53	L	2000-5000	DQ5	L	5001-9999	DQ6	L	5001-9999	DQ2	L	2000-5000	DQ7	L	2000-5000	DQ8	L	2000-5000	DQ9	L	<2000	DQ4	L	2000-5000	
24	DR8	L	5001-9999	DR9	L	5001-9999	DR10	L	5001-9999	DR51	L	5001-9999	DR52	L	5001-9999	DR53	L	2000-5000	DQ5	L	5001-9999	DQ6	L	5001-9999	DQ2	L	2000-5000	DQ7	L	2000-5000	DQ8	L	2000-5000	DQ9	L	2000-5000	DQ4	L	2000-5000	
25	NT																																							
26	DR8	L	2000-5000	DR9	L	2000-5000	DR10	L	2000-5000	DR51	L	2000-5000	DR52	L	2000-5000	DR53	L	<2000	DQ5	L	2000-5000	DQ6	L	2000-5000	DQ2	L	<2000	DQ7	L	2000-5000	DQ8	L	<2000	DQ9	L	<2000	DQ4	L	2000-5000	
28	DR8	L	5001-9999	DR9	L	5001-9999	DR10	L	5001-9999	DR51	L	5001-9999	DR52	L	5001-9999	DR53	L	2000-5000	DQ5	L	5001-9999	DQ6	L	5001-9999	DQ2	L	<2000	DQ7	L	2000-5000	DQ8	L	<2000	DQ9	L	<2000	DQ4	L	2000-5000	
34	DR8	L	5001-9999	DR9	L	2000-5000	DR10	L	2000-5000	DR51	L	2000-5000	DR52	L	5001-9999	DR53	L	2000-5000	DQ5	L	2000-5000	DQ6	L	5001-9999	DQ2	L	2000-5000	DQ7	L	2000-5000	DQ8	L	2000-5000	DQ9	L	2000-5000	DQ4	L	2000-5000	
35	DR8	L	5001-9999	DR9	L	2000-5000	DR10	L	5001-9999	DR51	L	5001-9999	DR52	L	5001-9999	DR53	L	2000-5000	DQ5	L	2000-5000	DQ6	L	2000-5000	DQ2	L	<2000, 2000-5000	DQ7	L	<2000, 2000-5000	DQ8	L	<2000	DQ9	L	<2000	DQ4	L	<2000	
38	DR8	L	>1000	DR9	L	>1000	DR10	L	>1000	DR51	L	5001-9999	DR52	L	>1000	DR53	L	2000-5000	DQ5	L	5001-9999	DQ6	L	5001-9999	DQ2	L	<2000	DQ7	L	2000-5000	DQ8	L	2000-5000	DQ9	L	2000-5000	DQ4	L	<2000	
39	DR8	L	5001-9999	DR9	L	2000-5000	DR10	L	2000-5000	DR51	L	2000-5000	DR52	L	5001-9999	DR53	L	2000-5000	DQ5	L	2000-5000	DQ6	L	2000-5000	DQ2	L	<2000	DQ7	L	<2000	DQ8	L	2000-5000	DQ9	L	2000-5000	DQ4	L	<2000	
41	DR8	L	>1000	DR9	L	>1000	DR10	L	>1000	DR51	L	5001-9999	DR52	L	>1000	DR53	L	2000-5000	DQ5	L	>1000	DQ6	L	>1000	DQ2	L	<2000	DQ7	L	5001-9999	DQ8	L	2000-5000	DQ9	L	2000-5000	DQ4	L	2000-5000	
42	DR8	L	5001-9999	DR9	L	5001-9999	DR10	L	5001-9999	DR51	L	5001-9999	DR52	L	5001-9999	DR53	L	2000-5000	DQ5	L	5001-9999	DQ6	L	5001-9999	DQ2	L	<2000	DQ7	L	2000-5000	DQ8	L	2000-5000	DQ9	L	2000-5000	DQ4	L	2000-5000	
45	DR8	L	5001-9999	DR9	L	2000-5000	DR10	L	2000-5000	DR51	L	5001-9999	DR52	L	5001-9999	DR53	L	2000-5000	DQ5	L	5001-9999	DQ6	L	2000-5000	DQ2	L	<2000	DQ7	L	<2000	DQ8	L	<2000	DQ9	L	<2000	DQ4	L	<2000	
48	DR8	L	>1000	DR9	L	5001-9999	DR10	L	5001-9999	DR51	L	5001-9999	DR52	L	5001-9999	DR53	L	2000-5000	DQ5	L	5001-9999	DQ6	L	5001-9999	DQ2	L	<2000	DQ7	L	<2000	DQ8	L	<2000	DQ9	L	<2000	DQ4	L	<2000	
51	NT																																							
54	DR8	L	>1000	DR9	L	5001-9999	DR10	L	>1000	DR51	L	5001-9999	DR52	L	>1000	DR53	L	5001-9999	DQ5	L	5001-9999	DQ6	L	>1000	DQ2	L	2000-5000	DQ7	L	5001-9999	DQ8	L	2000-5000	DQ9	L	2000-5000	DQ4	L	2000-5000	
58	DR8	L	>1000	DR9	L	5001-9999	DR10	L	5001-9999	DR51	L	5001-9999	DR52	L	>1000	DR53	L	5001-9999	DQ5	L	5001-9999	DQ6	L	5001-9999	DQ2	L	2000-5000	DQ7	L	5001-9999	DQ8	L	2000-5000	DQ9	L	2000-5000	DQ4	L	2000-5000	
62	DR8	L	5001-9999	DR9	L	5001-9999	DR10	L	5001-9999	DR51	L	5001-9999	DR52	L	5001-9999	DR53	L	2000-5000	DQ5	L	5001-9999	DQ6	L	5001-9999	DQ2	L	2000-5000	DQ7	L	2000-5000	DQ8	L	2000-5000	DQ9	L	2000-5000	DQ4	L	<2000	
100																																								
112																																								
114	DR8	L	>1000	DR9	L	5001-9999	DR10	L	5001-9999	DR51	L	5001-9999	DR52	L	>1000	DR53	L	2000-5000	DQ5	L	5001-9999	DQ6	L	5001-9999	DQ2	L	<2000	DQ7	L	2000-5000	DQ8	L	2000-5000	DQ9	L	2000-5000	DQ4	L	2000-5000	
116	DR8	L	>1000	DR9	L	5001-9999	DR10	L	>1000	DR51	L	5001-9999	DR52	L	>1000	DR53	L	5001-9999	DQ5	L	5001-9999	DQ6	L	5001-9999	DQ2	L	<2000	DQ7	L	2000-5000	DQ8	L	2000-5000	DQ9	L	2000-5000	DQ4	L	2000-5000	
117	DR8	L	5001-9999	DR9	L	5001-9999	DR10	L	5001-9999	DR51	L	5001-9999	DR52	L	5001-9999	DR53	L	2000-5000	DQ5	L	2000-5000	DQ6	L	2000-5000	DQ2	L	<2000	DQ7	L	2000-5000	DQ8	L	2000-5000	DQ9	L	2000-5000	DQ4	L	2000-5000	
119	DR8	L	>1000	DR9	L	5001-9999	DR10	L	5001-9999	DR51	L	5001-9999	DR52	L	>1000	DR53	L	5001-9999	DQ5	L	5001-9999	DQ6	L	5001-9999	DQ2	L	<2000	DQ7	L	2000-5000	DQ8	L	2000-5000	DQ9	L	2000-5000	DQ4	L	2000-5000	
120	DR8	L	>1000	DR9	L	5001-9999	DR10	L	5001-9999	DR51	L	5001-9999	DR52	L	>1000	DR53	L	5001-9999	DQ5	L	5001-9999	DQ6	L	5001-9999	DQ2	L	<2000	DQ7	L	2000-5000	DQ8	L	2000-5000	DQ9	L	2000-5000	DQ4	L	2000-5000	
133	NT																																							
136	DR8	L	>1000	DR9	L	5001-9999	DR10	L	5001-9999	DR51	L	5001-9999	DR52	L	5001-9999	DR53	L	2000-5000	DQ5	L	5001-9999	DQ6	L	5001-9999	DQ2	L	<2000	DQ7	L	2000-5000	DQ8	L	2000-5000	DQ9	L	2000-5000	DQ4	L	2000-5000	
142	DR8	L	5001-9999	DR9	L	5001-9999	DR10	L	5001-9999	DR51	L	5001-9999	DR52	L	5001-9999	DR53	L	2000-5000	DQ5	L	5001-9999	DQ6	L	5001-9999	DQ2	L	<2000	DQ7	L	2000-5000	DQ8	L	2000-5000	DQ9	L	2000-5000	DQ4	L	2000-5000	
143	DR8	L	>1000	DR9	L	>1000	DR10	L	>1000	DR51	L	>1000	DR52	L	>1000	DR53	L	>1000	DQ5	L	>1000	DQ6	L	>1000	DQ2	L	2000-5000	DQ7	L	5001-9999	DQ8	L	5001-9999	DQ9	L	5001-9999	DQ4	L	5001-9999	
145	DR8	L	>1000	DR9	L	5001-9999	>1000	DR10	L	>1000	DR51	L	5001-9999	DR52	L	>1000	DR53	L	5001-9999	DQ5	L	5001-9999	DQ6	L	5001-9999	DQ2	L	2000-5000	DQ7	L	2000-5000	5001-9999	DQ8	L	2000-5000	DQ9	L	<2000, 2000-5000		
149	DR8	L	5001-9999	DR9	L	5001-9999	DR10	L	5001-9999	DR51	L	5001-9999	DR52	L	5001-9999	DR53	L	2000-5000	DQ5	L	5001-9999	DQ6	L	5001-9999	DQ2	L	<2000	DQ7	L	2000-5000	DQ8	L								

UK NEQAS for H&I - SCHEME 3 - HLA ANTIBODY SPECIFICITY ANALYSIS

CLASS II HLA ANTIBODY SPECIFICITY ANALYSIS OF 310/2018

DESPATCHED ON 13 NOVEMBER 2018

Table with columns for Lab no., Consensus % reported, DPB1* Antibodies - NOT ASSESSED (01:01 to 28:01), and various assay results (spec, tech, MFI). The table contains data for lab numbers 9 through 411, with various 'Not Assessed' percentages for different DPB1* antibodies.

Technique : C = CDC; E = ELISA; F = Flow cytometry; L = Luminex; O = Other

Summary table with columns for Number reporting, Sepoficity, Total number of participants, and various assay results (spec, tech, MFI). It provides a breakdown of results across different DPB1* antibodies.

